Sort   by:  
 Page size 
ProteomicsBeta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts.
Rationale: The molecular underpinnings of heart failure with reduced ejection fraction (HFrEF) involves a complex remodeling of the contractile, metabolic and electrical functions. Current pharmacotherapy for patients presenting HFrEF includes combination of angiotensin-converting enzyme inhibitors ...
ORGANISM(S): Mus musculus (Mouse) 
2022-05-20 | PXD024525 | Pride
Ace inhibitor Hfref Cardiac proteomics ß-ar blocker Phosphoproteomics 
Proteomicsinvestigation of changes in the proteome and the phosphoproteome of the heart induced by exercise, either in control or in PKP2-deficient hearts in relation to ARVC
We performed an unbiased investigation of changes in the proteome and the phosphoproteome of the heart induced by exercise, either in control or in PKP2-deficient hearts. Two pairs of experimental groups were studied: The first pair consisted of control animals and the second pair of animals deficie...
ORGANISM(S): Mus musculus (Mouse) 
2022-11-04 | PXD025956 | Pride
Mouse Pkp2 Heart failure Cardiovascular Arvc 
Proteomicsarrythmogenic right ventricular acrdiomayopathy (PKP2-cko in mice and Human biopsies)
Summary: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disorder. It is classified as the second most common cause of unexpected sudden death by cardiac arrest in the young. ARVC has devastating psychosocial consequences, especially as many patients are young adults, ...
ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse) 
2022-11-04 | PXD025523 | Pride
Cardiovascular protemics Tmt Heart failure Arvc 
Sort   by:  
 Page size